[Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calcium].
To evaluate the effects of a long-term treatment with nandrolone decanoate on metabolism of the skeleton, a double-blind randomized study was carried out in women with joint diseases without metabolic bone derangement. Ten patients were treated with 50 mg of nandrolone decanoate every three weeks for two years; in six subjects a treatment with placebo was performed. As it concerns plasma calcium and phosphate, serum alkaline phosphatase, urinary excretion of calcium, phosphate, hydroxyproline and cAMP, as parathyroid index, it was not observed significant differences in the two examined groups. While in placebo group at the end of the study the intestinal radiocalcium remained unchanged and bone mineral content showed a slight decrease, on the contrary nandrolone decanoate treatment promoted a significant improvement in intestinal calcium absorption and an increase in bone mineral content.
D000249:Adenosine Monophosphate / Q000652:urine; D045930:Anabolic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D008903:Minerals / Q000378:metabolism*; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D010003:Osteoarthritis / Q000188:drug therapy; D011897:Random Allocation
D045930:Anabolic Agents; D008903:Minerals; D000249:Adenosine Monophosphate; D009277:Nandrolone; D000077603:Nandrolone Decanoate; D002118:Calcium
Effetti del nandrolone decanoato sul contenuto minerale osseo e sull'assorbimento intestinale del calcio.